Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Iovance Biotherapeutics (IOVA) over the last 8 years, with Q3 2025 value amounting to $120.0 million.

  • Iovance Biotherapeutics' Change in Acquisitions & Divestments rose 909.09% to $120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $446.0 million, marking a year-over-year increase of 2742.86%. This contributed to the annual value of $428.0 million for FY2024, which is 4986.89% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Change in Acquisitions & Divestments of $120.0 million as of Q3 2025, which was up 909.09% from $90.0 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Change in Acquisitions & Divestments' 5-year high stood at $164.4 million during Q1 2023, with a 5-year trough of $21.0 million in Q3 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Change in Acquisitions & Divestments value was $110.0 million (recorded in 2024), while the average stood at $94.9 million.
  • The largest annual percentage gain for Iovance Biotherapeutics' Change in Acquisitions & Divestments in the last 5 years was 42505.97% (2024), contrasted with its biggest fall of 4707.48% (2024).
  • Iovance Biotherapeutics' Change in Acquisitions & Divestments (Quarter) stood at $38.0 million in 2023, then surged by 205.26% to $116.0 million in 2024, then increased by 3.45% to $120.0 million in 2025.
  • Its last three reported values are $120.0 million in Q3 2025, $90.0 million for Q2 2025, and $120.0 million during Q1 2025.